Headlines
Headlines

Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing

Menlo Park, CA., June 22, 2022 (GLOBE NEWSWIRE) — Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced today the closing of a $119 million financing round led by Enavate Sciences, a portfolio company created by Patient Square Capital. Additional investors participating in the financing include Alladapt’s founding investor, Gurnet Point Capital, along with new investors Allerfund, Novartis (NYSE: NVS), Red Tree Venture Capital, and WestRiver Group. More

Read More »
Headlines
Headlines

Inimmune’s new CEO Alan Joslyn takes the helm

Missoula, MT., June 21, 2022 (PRNewswire) — Inimmune Corp., a leader in developing the next generation of vaccines and immunotherapeutics, announced today that Dr. Alan Joslyn has been appointed President and Chief Executive Officer of the company. Dr. Joslyn will also join the Inimmune Board of Directors as CEO. More

Read More »
Headlines
Headlines

Precision BioSciences and Novartis ink 1.5B In Vivo Gene Editing Collaboration

Durham, N.C. June 21, 2022 (BUSINESS WIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the “Agreement”). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta thalassemia. More

Read More »
Headlines
Headlines

Israel’s Aidoc raises $110m for AI tech that reads imaging scans

New York, NY, June 20, 2022 (The Times of Israel) — Aidoc, a maker of AI-based software that helps radiologists read medical scans and alerts them to strokes or pulmonary embolisms, has pulled in a $110 million Series D investment round to expand the development of its technology, sales and its market reach, the company said last week. More

Read More »
Headlines
Headlines

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

Philadelphia, PA.,  June 8, 2022 (PRNewswire) — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, today announced the completion of an oversubscribed and up-sized $118 million Series B financing. More

Read More »
Headlines
Headlines

Better Therapeutics Appoints Frank Karbe as Chief Executive Officer

San Francisco, CA, June 7, 2022 (BUSINESS WIRE) — Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. More

Read More »
Headlines
Headlines

Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Cambridge, MA., June 2, 2022 (BUSINESS WIRE) — Flagship Pioneering, the bioplatform innovation company, andTessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined Tessera as Chief Executive Officer. Dr. Severino, who was previously Vice Chairman and President of AbbVie, also serves as a Flagship Pioneering CEO-Partner. More

Read More »
Headlines
Headlines

Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases

Waltham, MA., June 2, 2022 (BUSINESS WIRE) — Upstream Bio, a biotech company focused on inflammation, today debuted with a $200 million Series A financing. The funding will allow Upstream to advance the company’s lead program UPB-101, a clinical-stage monoclonal antibody targeting the TSLP receptor, and build a pipeline of assets to address immune-mediated diseases. The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital, and Altshuler Shaham Provident Funds Ltd. More

Read More »
Headlines
Headlines

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

South San Francisco, CA., May 25, 2022 (BUSINESS WIRE) –Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing. The round was co-led by OrbiMed and Third Rock Ventures. Proceeds from the financing will be used to advance Terremoto’s lysine-targeted covalency platform and develop best-in-class therapies against known drug targets, as well as first-in-class medicines against the previously undruggable. More

Read More »
Headlines
Headlines

Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Seoul, KR., May 24, 2022 — (BUSINESS WIRE) –Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the appointment of Neil Warma as its President and Chief Executive Officer. Mr. Warma who has over 25 years of experience as a global entrepreneur, company builder and successful CEO will lead Genexine onto the world stage with a focus on advancing Genexine’s key products to market, expanding its pipeline and focusing on global drug development. More

Read More »
Headlines
Headlines

Britt Meelby Jensen appointed new CEO of Ambu

Columbia, MD, May 19, 2022 (Globe Newswire) — The Board of Directors of Ambu A/S has appointed Britt Meelby Jensen as new Chief Executive Officer (CEO). Britt Meelby Jensen has served as board member of Ambu since 2019, a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will leave Ambu after three years and support the new CEO in the transition as needed. More

Read More »
Headlines
Headlines

Laekna Therapeutics Raises $61 Million in Series D financing

Shanghai and Warren, N.J., May 18, 2022 (PRNewswire) —  Laekna Therapeutics (“Laekna”), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised $61 million in Series D financing led by CS Capital with support from Worldstar, and Infinity Capital. Yanchuang Capital as the existing investor continued to support the company with additional funding. More

Read More »